Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Integrase inhibitors associated with improved viral suppression in HIV

The integrase inhibitor Tivicay combined with low-dose Sustiva was associated with higher rates of long-term viral suppression than standard-dose Sustiva in patients with HIV, data from a network meta-analysis indicated.

Published
29 September 2016
From
Healio
UNC Receives $18 Million to Combine Tech & Health

"iTech will be home to six studies with each study using technology to address a barrier to the HIV care continuum,” said Hightow-Weidman. “For youth at risk of becoming infected with HIV, we will develop apps that list HIV testing sites and medical providers who prescribe pre-exposure prophylaxis or PrEP to prevent HIV. For youth who test positive for the virus, we will develop electronic health interventions to engage them in care and improve adherence to antiretroviral therapy.”

Published
28 September 2016
From
University of North Carolina Institute for Global Health & Infectious Diseases
EASL issues new hepatitis C treatment recommendations for all genotypes

The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris.

Published
26 September 2016
By
Liz Highleyman
Spanish study gives reassurance: small HIV blips do not predict treatment failure

A very low viral load (20-49 copies/ml) during HIV therapy does not increase the risk of the subsequent virological failure of treatment (viral load above 200 copies/ml), according

Published
21 September 2016
By
Michael Carter
Targeting dormant HIV

Why wake up the virus? To better kill it, of course. A team from the University of Montreal Hospital Research Centre (CRCHUM) has taken an important step forward in the search for a HIV/AIDS cure. The laboratory of Dr. Daniel Kaufmann has developed a highly accurate technique for detecting the rare cells that hide the virus and prevent current therapies from curing HIV infection.

Published
20 September 2016
From
HIV / AIDS News From Medical News Today
Four day a week ART: sub-optimal drug levels but few virological failures

A poster at IAS 2016 reported on the effectiveness of a strategy in France to use reduced dose maintenance therapy. This involved only taking ART for four rather than seven days a week.

Published
20 September 2016
From
HIV i-Base
Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

Published
20 September 2016
From
BETA blog
Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency

If approved, this tablet would be the first protease inhibitor-based STR option indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adults and adolescents. This new treatment would combine the protease inhibitor, darunavir (DRV, D, 800 mg), with the pharmacokinetic enhancer, cobicistat (COBI, C, 150 mg) and the nucleoside reverse transcriptase inhibitors emtricitabine (FTC, F, 200 mg) and tenofovir alafenamide (TAF 10 mg), in one single tablet.

Published
13 September 2016
From
Janssen-Cilag press release
Delays in updating HIV treatment guidelines in Africa blocking early treatment for millions

Delays in adopting the World Health Organization (WHO) 2015 recommendation of HIV treatment for all threaten the achievement of the 90-90-90 targets for HIV diagnosis and viral

Published
12 September 2016
By
Keith Alcorn
Evidence that “on-demand” PrEP taken before and after sex can prevent HIV

How many doses of Truvada-based PrEP (pre-exposure prophylaxis) are needed to provide adequate protection against HIV? Might it be possible to take PrEP only before and after sex—instead of every day?

Published
12 September 2016
From
BETA blog
← First12345...425Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close